as 02-14-2025 4:00pm EST
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Founded: | 2015 | Country: | United States |
Employees: | N/A | City: | SAN DIEGO |
Market Cap: | 1.1B | IPO Year: | N/A |
Target Price: | $26.00 | AVG Volume (30 days): | 1.3M |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.51 | EPS Growth: | N/A |
52 Week Low/High: | $6.70 - $18.51 | Next Earning Date: | 03-20-2025 |
Revenue: | $2,568,000 | Revenue Growth: | 8460.00% |
Revenue Growth (this year): | 68783.34% | Revenue Growth (next year): | 503.87% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Shawver Laura | SPRY | Director | Jan 6 '25 | Sell | $11.10 | 50,000 | $555,065.00 | 210,346 | |
Lowenthal Richard E | SPRY | PRESIDENT AND CEO | Dec 17 '24 | Sell | $11.67 | 100,000 | $1,167,100.00 | 1,297,447 | |
Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | Dec 17 '24 | Sell | $11.67 | 100,000 | $1,167,100.00 | 1,098,499 | |
Chakma Justin | SPRY | Chief Business Officer | Dec 12 '24 | Sell | $12.16 | 144,605 | $1,768,092.94 | 136,380 | |
Dorsey Brian | SPRY | Chief Operating Officer | Dec 11 '24 | Sell | $12.36 | 40,000 | $493,858.50 | 6,024 | |
Lowenthal Richard E | SPRY | PRESIDENT AND CEO | Dec 10 '24 | Sell | $13.16 | 100,000 | $1,316,420.00 | 1,297,447 | |
Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | Dec 10 '24 | Sell | $13.16 | 100,000 | $1,316,420.00 | 1,098,499 | |
Chakma Justin | SPRY | Chief Business Officer | Dec 10 '24 | Sell | $13.15 | 50,000 | $657,625.00 | 136,380 | |
Chakma Justin | SPRY | Chief Business Officer | Dec 4 '24 | Sell | $14.11 | 144,640 | $2,041,200.04 | 136,380 | |
Karas Eric | SPRY | Chief Commercial Officer | Dec 2 '24 | Sell | $14.06 | 10,000 | $140,423.37 | 5,693 |
SPRY Breaking Stock News: Dive into SPRY Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
MT Newswires
10 days ago
GlobeNewswire
11 days ago
Simply Wall St.
16 days ago
MT Newswires
18 days ago
GlobeNewswire
a month ago
Investor's Business Daily
a month ago
Simply Wall St.
a month ago
The information presented on this page, "SPRY ARS Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.